MP76-08 ERECTILE AND EJACULATORY FUNCTION AFTER REZUM WATER VAPOUR THERMAL THERAPY AT 12- AND 24-MONTHS FOLLOW-UP

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP76-08 ERECTILE AND EJACULATORY FUNCTION AFTER REZUM WATER VAPOUR THERMAL THERAPY AT 12- AND 24-MONTHS FOLLOW-UP Dean Elterman, Naeem Bhojani, Bilal Chughtai, and Kevin C. Zorn Dean EltermanDean Elterman More articles by this author , Naeem BhojaniNaeem Bhojani More articles by this author , Bilal ChughtaiBilal Chughtai More articles by this author , and Kevin C. ZornKevin C. Zorn More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003350.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Rezūm convective water vapour thermal therapy is a minimally invasive, office-based treatment for benign prostatic hyperplasia (BPH). While studies have demonstrated its efficacy in symptomatic improvement, it’s impact on longer term sexual function in the real world has been underreported. The purpose of this study was to evaluate the change in MSHQ function and bother, and IIEF at 12 and 24 months after Rezum treatment. METHODS: Change in MSHQ Bother, MSHQ Function and IIEF-15 from baseline to 12 months, and baseline to 24 months, were modelled using linear mixed models. For MSHQ Bother, a baseline cutoff of 3 was used; for MSHQ Function, the median (9) was used as the cutoff; for IIEF-15, the median (54) was used. RESULTS: Change in MSHQ bother are stratified by baseline score of <3 vs. ≥3 (i.e. moderately bothered). Patients with a baseline MSHQ bother of ≥3 had a significantly greater decrease in 12-month MSHQ compared to patients with a baseline score of <3. Mean difference=-2.94 (95% CI: -3.66, -2.22), p<0.001. Patients with a baseline MSHQ bother of ≥3 had a significantly greater decrease in 24-month MSHQ compared to patients with a baseline score of <3. Mean difference=-2.84 (95% CI: -4.22, -1.46), p<0.001. Change in MSHQ function are stratified by the median (<9 vs. ≥9). Patients with a baseline MSHQ function score of ≥9 had a significantly greater decrease in 24-month MSHQ function score compared to patients with a baseline score of <9. Mean difference=-3.37 (95% CI: -5.40, -1.33), p=0.002. Patients with a baseline MSHQ function score of ≥9 had a significantly greater decrease in 24-month MSHQ function score compared to patients with a baseline score of<9. Mean difference=-4.55 (95% CI: -7.88, -1.22), p=0.009. Change in IIEF function are stratified by the median (<54 vs. ≥54). Patients with a baseline MSHQ function score of ≥54 had a significantly greater decrease in 24-month MSHQ function score compared to patients with a baseline score of <54. Mean difference=-13.36 (95% CI: -21.04, -6.27), p<0.001. Patients with a baseline MSHQ function score of ≥54 had a greater decrease in 24 months MSHQ function score compared to patients with a baseline score of <54, though the difference was not statistically significant. Mean difference=-7.94 (95% CI: -16.59, 0.70), p=0.07 CONCLUSIONS: In this cohort of men treated with office-based, outpatient Rezūm for BPH, baseline MSHQ function and bother score, along with median IIEF predicted preservation or decline in sexual function after 12 and 24 months. Source of Funding: No © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e1093 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Dean Elterman More articles by this author Naeem Bhojani More articles by this author Bilal Chughtai More articles by this author Kevin C. Zorn More articles by this author Expand All Advertisement PDF downloadLoading ...